Hypopharyngeal Cancer – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Hypopharyngeal Cancer – Pipeline Review, H2 2019’, provides an overview of the Hypopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Hypopharyngeal Cancer

– The report reviews pipeline therapeutics for Hypopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hypopharyngeal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Hypopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hypopharyngeal Cancer”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hypopharyngeal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hypopharyngeal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Ascenta Therapeutics Inc

AstraZeneca Plc

Biomimetix JV LLC

Boehringer Ingelheim International GmbH

Celldex Therapeutics Inc

Eisai Co Ltd

GlaxoSmithKline Plc

Incyte Corp

Innate Pharma SA

Merck & Co Inc

Ono Pharmaceutical Co Ltd

Shionogi & Co Ltd

VasGene Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Hypopharyngeal Cancer - Overview 5

Hypopharyngeal Cancer - Therapeutics Development 6

Hypopharyngeal Cancer - Therapeutics Assessment 12

Hypopharyngeal Cancer - Companies Involved in Therapeutics Development 20

Hypopharyngeal Cancer - Drug Profiles 25

Hypopharyngeal Cancer - Dormant Projects 170

Hypopharyngeal Cancer - Discontinued Products 171

Appendix 172

List of Tables

“List of Tables

Table 1: Number of Products under Development for Hypopharyngeal Cancer, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Universities/Institutes, H2 2019

Table 4: Products under Development by Companies, H2 2019

Table 5: Products under Development by Universities/Institutes, H2 2019

Table 6: Number of Products by Stage and Target, H2 2019

Table 7: Number of Products by Stage and Mechanism of Action, H2 2019

Table 8: Number of Products by Stage and Route of Administration, H2 2019

Table 9: Number of Products by Stage and Molecule Type, H2 2019

Table 10: Hypopharyngeal Cancer – Pipeline by Ascenta Therapeutics Inc, H2 2019

Table 11: Hypopharyngeal Cancer – Pipeline by AstraZeneca Plc, H2 2019

Table 12: Hypopharyngeal Cancer – Pipeline by Biomimetix JV LLC, H2 2019

Table 13: Hypopharyngeal Cancer – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 14: Hypopharyngeal Cancer – Pipeline by Celldex Therapeutics Inc, H2 2019

Table 15: Hypopharyngeal Cancer – Pipeline by Eisai Co Ltd, H2 2019

Table 16: Hypopharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2019

Table 17: Hypopharyngeal Cancer – Pipeline by Incyte Corp, H2 2019

Table 18: Hypopharyngeal Cancer – Pipeline by Innate Pharma SA, H2 2019

Table 19: Hypopharyngeal Cancer – Pipeline by Merck & Co Inc, H2 2019

Table 20: Hypopharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2019

Table 21: Hypopharyngeal Cancer – Pipeline by Shionogi & Co Ltd, H2 2019

Table 22: Hypopharyngeal Cancer – Pipeline by VasGene Therapeutics Inc, H2 2019

Table 23: Hypopharyngeal Cancer – Dormant Projects, H2 2019

Table 24: Hypopharyngeal Cancer – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Hypopharyngeal Cancer, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products by Top 10 Targets, H2 2019

Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Molecule Types, H2 2019

Figure 10: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports